IMpower131: Progression-free Survival (PFS) and Overall Survival (OS) Analysis of a Randomised Phase III Study of Atezolizumab + Carboplatin + Paclitaxel or Nab-Paclitaxel Vs Carboplatin + Nab-Paclitaxel in 1L Advanced Squamous NSCLC.

M. A. Socinski,A. Rittmeyer, D. Shapovalov,F. Orlandi,M. McCleod,R. A. Soo, R. Palmero,T. Kozuki,M. R. Migliorino, K. D. Koynov,H. Berard,B. G. M. Hughes,W. Yu,V. Graupner,S. W. Sun,M. Kowanetz,T. Hoang,W. Lin,R. M. Jotte

Annals of oncology（2018）

Cited 33|Views67

No score

Abstract

Background: Combining atezolizumab (atezo; anti–PD-L1) and chemotherapy (chemo) may further improve outcomes in NSCLC by enhancing immunomodulatory effects. IMpower131 (NCT02367794) is a randomised Ph III trial of atezo + chemo vs chemo alone in 1L Stage IV squamous NSCLC. In the primary analysis, PFS benefit was seen with atezo + carboplatin (carbo) + nab-paclitaxel (nab-pac) vs carbo + nab-pac (HR, 0.71; 95% CI: 0.60, 0.85; P=0.0001), with a tolerable safety profile. Here we report updated results at the second interim OS analysis (Arm B vs C).

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined